Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $8.4500 (1.93%) ($7.8800 - $8.5600) on Thu. Mar. 19, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.96% (three month average) | RSI | 49 | Latest Price | $8.4500(1.93%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 4.8% a day on average for past five trading days. | Weekly Trend | FOLD declines -7.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(55%) XBI(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -3.48% in a week (0% probabilities). VIXM(-31%) VXX(-18%) TLT(-12%) IGOV(-5%) TIP(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.48% (StdDev 6.96%) | Hourly BBV | 0 () | Intraday Trend | 3.2% | | | |
|
1 - 5 Day Possible Target | $-14.58(-272.54%) | Resistance Level | $8.92 | 5 Day Moving Average | $8.06(4.84%) | 10 Day Moving Average | $8.16(3.55%) | 20 Day Moving Average | $8.92(-5.27%) | To recent high | -24.3% | To recent low | 27.5% | Market Cap | $2.182b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |